Literature DB >> 15481741

Enzyme replacement as an effective treatment for the common symptoms of complex carbohydrate intolerance.

Barbara Levine1, Steven Weisman.   

Abstract

Complex carbohydrates are an essential part of a healthy diet. However, many people suffer from varying degrees of carbohydrate intolerance, resulting in embarrassing gastrointestinal symptoms and avoidance of these components of a healthy diet. To facilitate awareness and discussion, we propose the phrase "complex carbohydrate intolerance" (CCI) as a broad term to encompass the range of symptoms associated with carbohydrate intolerance. While various treatments offer symptomatic relief, enzyme replacement therapy targets the cause of the problem: an enzyme deficiency. The enzyme, alpha-galactosidase, currently only found in the over-the-counter product, Beano, may be an effective preventative treatment for CCI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15481741

Source DB:  PubMed          Journal:  Nutr Clin Care        ISSN: 1096-6781


  4 in total

1.  Variable Use of Disaccharidase Assays When Evaluating Abdominal Pain.

Authors:  Stanley A Cohen; Hannah Oloyede
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-01

2.  A pilot trial on subjects with lactose and/or oligosaccharides intolerance treated with a fixed mixture of pure and enteric-coated α- and β-galactosidase.

Authors:  Francesco Di Pierro; Alexander Bertuccioli; Eleonora Marini; Leandro Ivaldi
Journal:  Clin Exp Gastroenterol       Date:  2015-02-19

3.  Valuation of agro-industrial wastes as substrates for heterologous production of α-galactosidase.

Authors:  María-Efigenia Álvarez-Cao; Agustín Rico-Díaz; María-Esperanza Cerdán; Manuel Becerra; María-Isabel González-Siso
Journal:  Microb Cell Fact       Date:  2018-09-03       Impact factor: 5.328

4.  Optimization of Saccharomyces cerevisiae α-galactosidase production and application in the degradation of raffinose family oligosaccharides.

Authors:  María-Efigenia Álvarez-Cao; María-Esperanza Cerdán; María-Isabel González-Siso; Manuel Becerra
Journal:  Microb Cell Fact       Date:  2019-10-10       Impact factor: 5.328

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.